VTYX Surges 83% After Positive Phase 2 Data for VTX3232.

Shares of Ventyx Biosciences surged 83% after hours on positive Phase 2 data for VTX3232, an oral NLRP3 inhibitor targeting obesity and cardiovascular risk. The drug showed rapid and substantial reductions in inflammation, with hsCRP levels dropping 80% within the first week and IL-6 levels falling below the cardiovascular risk threshold by Week 12. The company reported strong safety and tolerability, with no impact on weight in both monotherapy and combination arms.